The patient perspective on MRD

Many patients with lymphoid cancer actively partner with their care teams in setting treatment goals and establishing care plans. Hear from patients in their own words about how MRD testing has provided greater insight throughout their care and enabled them to make more informed decisions.

As a patient with high-risk myeloma, Tim shares his experiences and insights on what MRD testing means for patients.

Lee shares his journey as a patient with chronic lymphocytic leukemia (CLL) and how MRD testing has given him peace of mind.

When Patients Become Advocates

Patient-driven advocacy and education on the topic of MRD is an important source of credible information for patients. See what patient advocates have to say about MRD and clonoSEQ.

This page is intended for use by healthcare professionals of the United States.

clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit

Test Your clonoSEQ Knowledge

How much do you know about clonoSEQ MRD testing in clinical practice?

clonoSEQ MRD Quiz